期刊文献+

左乙拉西坦单药治疗各型癫癎的疗效和安全性临床观察 被引量:2

原文传递
导出
摘要 目的对50例单独应用左乙拉西坦(LEV)的癫癎患者进行临床观察和随访,以评估左乙拉西坦治疗各型癫癎的疗效和安全性。方法采用开放性自身对照方法对2009年6月~2010年3月本院及其门诊就诊的50例左乙拉西坦单药治疗的癫癎患者进行随访研究,收集治疗前后患者发作频率变化、发作情况、不良反应以及退出原因。其随访均在半年以上。结果 LEV单药治疗后癫癎发作完全控制率48%,有效率38%;其中部分性发作完全控制率40.9%,有效率45.5%;全面性发作完全控制率53.6%,有效率32.1%,对west综合症亦有效。不良反应包括情绪异常、易激惹12%(6/50),头晕8%(4/50),白细胞减少2%(1/50);上述不良反应均为一过性,在2~5周内自然消失,未导致停药,未发现过敏以及肝、肾功能异常等严重不良反应。结论 LEV是一种安全有效的抗癫癎药物,对部分性和全面性发作均有效,且安全耐受性较好。
出处 《卒中与神经疾病》 2011年第1期32-34,共3页 Stroke and Nervous Diseases
  • 相关文献

参考文献6

  • 1Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binging site for the antiepileptie drug IevetiracetarrL Proc Natl Acad Sci USA, 2004, 101 (26):9861-9866. 被引量:1
  • 2田国红,赵忠新.左乙拉西坦——一种具有全新作用机制的抗癫痫新药[J].中国新药与临床杂志,2006,25(10):782-786. 被引量:43
  • 3Khurana DS, Kothare SV, Valencia I, Melvin JJ, Legido A. Levetiracetam monotherapy in children with epilepsy. Pediater Neurol, 2007, 36(4):227-230. 被引量:1
  • 4Perry S, Holt P, Benatar M. Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of age. J Child Neurol, 2008, 23(5):515-519. 被引量:1
  • 5Callenbach PM, Arts WF, ten Houten R, et al. Add-on levetiracetam in children and adolescents with refractory epilepsy: resuits of an open-label multi-centre study. Eur J Paediatr Neurol, 2008, 12(4) :321-327. 被引量:1
  • 6Peltola J, Peltola M, Auvinen A, et al. Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a singlecenter study. Acta Neurol Scand, 2008, 117(5):332-336. 被引量:1

二级参考文献27

  • 1ZONA C, NIESPODZIANY I, MARCHETYI C, et al. Levetiracetam does not modulate neuronal voltage-gated Na^+ and T-type Ca^2+ currents[J]. Seizure, 2001, 10(4) :279-286. 被引量:1
  • 2KLITGAARD H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?[J]. Epilepsia, 2001, 42 Suppl 4:13-18. 被引量:1
  • 3NIESPODZIANY I, KLITGAARD H, MARGINEANU DG. Levetiracetam inhibits the high-voltage-activated Ca (^2+) current in pyramidal neurones of rat hippoeampal slices[J]. Neurosci Lett, 2001, 306(1-2):5-8. 被引量:1
  • 4RIGO JM, HANS G, NGUYEN L. et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA-and glycine-gated currents[J]. Br J Pharmacol, 2002, 136(5) :659-672. 被引量:1
  • 5MADEJA M, MARGINEANU DG, GORjI A, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action?[J]. Neuropharmacology,2003, 45(5) :661-671. 被引量:1
  • 6LOSCHER W, HONACK D, RUNDFELDT C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy[J]. J Phannacol Exp Ther, 1998, 284(2) :474-479. 被引量:1
  • 7KLITGAARD H, MATAGNE A, GOBERT J. et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy[J]. Eur J Pharmacol, 1998, 353 (2-3) : 191-206. 被引量:1
  • 8TONG X, PATSALOS PN. A microdialysis study of the novel antiepileptic drug levetiraeetam: extracellular pharmaeokinetics and effect on taurine in rat brain[J]. Br J Pharmacol, 2001,133(6) :867-874. 被引量:1
  • 9BROCKMOLLER J, THOMSEN T, WITTSTOCK M, et al.Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C) :characterization by dynamic liver function tests[J]. Clin Pharmacol Ther, 2005, 77(6) :529-541. 被引量:1
  • 10SHORVON SD, LOWENTHAL A, JANZ D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures[J]. Epilepsia, 2000, 41 (9) : 1179-1186. 被引量:1

共引文献42

同被引文献27

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部